ANVS (Annovis Bio Inc.) stock: $0.83, $35.6M market cap, $18.7M cash, $16.9M EV, $52.8M fully diluted market cap. Next expected readout: Dec-27. Lead program: buntanetap/posiphen (Early Alzheimers Disease), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Our Company We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Parkinson's disease dementia (PDD)(Stage not disclosed)
Catalysts
— October 2026
Status note Lead product candidate. Pivotal Phase 3 early-AD trial (NCT06709014) fully enrolled with 860 patients as of July 2026. Phase 3 PD trial completed December 2023 (topline July 2024); OLE PD study initiated January 2026. FDA approved protocol for a pivotal Phase 3 in PDD (not yet initiated).
Partnerships National Institutes of Health (NIH): conducted and financed the completed single-ascending-dose Phase 1 trial
Indications
Advanced Alzheimer's disease(Phase 1)
Status note Completed single-ascending-dose Phase 1 trial, conducted and financed by NIH.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.